Aguilar Hinojosa NK, Figueroa Saavedra EI. Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso.
REVISTA ALERGIA MÉXICO 2023;
70:159-162. [PMID:
37933925 DOI:
10.29262/ram.v70i3.1256]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/05/2023] [Indexed: 11/08/2023] Open
Abstract
Background
Deferasirox is an active iron chelator, used in the treatment of iron overload such as hemochromatosis. Up to 28% may present adverse reactions to said drug. A desensitization protocol for this drug may be useful when there are no other therapeutic options.
Case report
A 52-year-old female with a diagnosis of hemochromatosis who began treatment with phlebotomy, poor response and tolerance, so it was decided to treat with deferasirox 500 mg daily, presenting symptoms of urticaria and angioedema on the third dose. Hospitalization was decided for a desensitization protocol with an initial dose of 0.6mg with a gradual increase in the dose, reaching a maintenance dose of 500 mg per day on the third day.
Conclusions
The rapid desensitization protocol for Deferasirox is useful when there is no response or therapeutic alternative.
Collapse